AUDJPY Shorts: Is there a balm in Gilead?

Well, sort of.
After Wednesday's initial enthusiasm for the pharmaceutical company Gilead's COVID19 treatment, Remdesivir, the market returned back to risk off yesterday lunchtime. The ECB's actions, or rather lack of action, left investors selling European stocks. That negative sentiment shortly flowed through into the US cash open and the previous gains were quickly replaced by